Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• New clinical trial seeks better treatment for indolent systemic mastocytosis

  The HARBOR study will compare elenestinib with a placebo and best supportive care to determine its effectiveness in treating ISM.

• AI predicts systemic mastocytosis risk using electronic health records

  AI models analyzed electronic health records to predict which patients may have undiagnosed systemic mastocytosis.

• Study finds TikTok videos on MCAS are filled with misinformation

  The study highlights the risks of relying on social media for medical advice.

• Case study: Mast cell leukemia’s rare presentation complicates diagnosis

  A recent case study describes how mast cell leukemia can present unusual symptoms that complicate diagnosis.

• New review analyzes bone disease in systemic mastocytosis

  Systemic mastocytosis (SM) can lead to severe osteoporosis, bone pain and fractures, requiring specialized treatment.

• Study urges early diagnosis and treatment of mast cell disorders to screen out SM

  Many cases of cutaneous mastocytosis remain confined to the skin, but some may indicate a risk for systemic mastocytosis (SM).

• Genetic variant in SM linked to higher risks during venom immunotherapy

  Patients with SM and venom allergies may face increased risks during immunotherapy if they have a particular genetic variant.

• Advanced SM linked to elevated sclerostin levels

  Patients with advanced mastocytosis showed significantly higher sclerostin concentrations, especially in those with bone disease.

• SM and other types of mastocytosis are more common than previously reported

  Improved diagnostics resulted in a higher prevalence of mastocytosis, including SM, than earlier reported, a new study said.

• Avapritinib improved survival and treatment duration in advanced SM

  Avapritinib significantly improved overall survival in patients with SM compared to midostaurin or best available therapy.